SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

AntriaBio, Inc. (ANTB)

ANTB RSS Feed
Add ANTB Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 12/8/2016 11:31:34 AM - Followers: 6 - Board type: Free - Posts Today: 0

AntriaBioAntriaBio, Inc.
890 Santa Cruz Avenue
Menlo Park, CA 94025
P: (650) 223-5441
info@antriabio.com

Reverse Merger 


Jan 7, 2013 - AntriaBio, Inc., a biopharmaceutical company developing novel therapeutics for the diabetes market, is pleased to announce the acquisition of the significant assets of PR Pharmaceuticals, Inc. and its intention to become a publicly traded company through a merger.

"AB101 has the potential to be a clearly differentiated product that represents a significant advance in basal insulin delivery," said Nevan Elam, AntriaBio's President and CEO. "AB101 may offer significant advantages over basal insulin products sold by Sanofi-Aventis and Novo Nordisk, which together sell more than $7B annually."



AntriaBio's lead diabetes product candidate, AB101, is a once-a-week injectable basal insulin that is currently in preclinical development. AB101 is administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia.

The formulation has been designed to release insulin slowly and uniformly over a period of approximately one week without an adverse initial burst of insulin. The release profile results in a low and sustained insulin level which supplements the effects of endogenous and exogenous insulin and complements the effects of orally administered hypoglycemic agents. AB101 has the potential to be a clearly differentiated product that represents a significant advance in basal insulin delivery.

AB101's long duration of action is the result of our ability to PEGylate insulin and then encapsulate it into poly-lactic, poly-glycolic (PLGA) microspheres. Currently available PEGylated biomolecules typically use large molecular weight PEG chains to decrease clearance and therefore reduce injection frequency. However, we use a very small molecular weight PEG for AB101 to modify the solubility of insulin and permit encapsulation of the drug into a biodegradable polymer.

After injection, the PEGylated insulin is slowly released at the injection site as the polymer microspheres are broken down by simple hydrolysis. Not only is our technology is unique, but also AB101 does not contain any new excipients and regulatory authorities have already approved numerous products using PEG or biodegradable polymers.

In addition to the proprietary technology for PEGylation of insulin and incorporation of the PEGylated insulin into biodegradable polymers, we have licensed proprietary microparticle manufacturing technology. The microsphere manufacturing process ensures production of a very tight particle size distribution with uniformly small microparticles. This is important to improve manufacturing efficiency and yields as well as to facilitate patient comfort by producing microspheres that can be injected through 25 gauge or smaller needles.



 

AntriaBio Appoints Two Industry Leaders to its Management Team
 
Menlo Park, CA - February 19th, 2013 - AntriaBio, Inc. is pleased to announce the appointment, on January 31, 2013, of two new members to its management team: Nevan Elam, AntriaBio's President and Chief Executive Officer and Sankaram Mantripragada, Ph.D, as AntriaBio's Chief Scientific Officer.
 
Nevan Elam has spent his entire career starting, managing and advising emerging growth companies in key areas of business including finance, marketing and clinical development. Prior to joining AntriaBio, Mr. Elam served as Chief Executive Officer of AeroSurgical Limited, a medical device company based in Europe. Prior to that, he directed the Pulmonary Business Unit of Nektar Therapeutics, which was sold to Novartis in 2008.
 
Mr. Elam also serves as a managing director of Konus Advisory Group, Inc. ("Konus"), a boutique healthcare consulting and investment firm that specializes in working with U.S. and European healthcare organizations on business opportunities in Asia, Latin America and the Middle East. Mr. Elam holds a J.D. from Harvard University and Bachelor's degree from Howard University.
 
Sankaram Mantripragada, Ph.D. brings to AntriaBio his strong understanding of the diabetes market and AntriaBio's unique platform technology. From June 2005 until October 2009, Dr. Mantripragada served as Vice President of R&D at PR Pharmaceuticals, Inc. ("PRP"). In January 2013, AntriaBio purchased substantially all of the PRP assets including significant technology, formulation, manufacturing, and intellectual property assets, which together form the basis of AntriaBio's drug development portfolio.
 
"Dr. Mantripragada's history with PRP's technology and formulation assets and his deep experience in diabetes products and markets make him a clear choice to lead our product development efforts," said Steve Howe, Chairman of AntriaBio. Mr. Howe served as Chairman and Chief Executive Officer of PRP from its formation in 1998 to 2010.
 
Dr. Mantripragada has been an advisor to companies specializing in diabetes, cell based therapies and cardiovascular diseases. He is listed as an inventor on more than 8 patents.
 
Prior to joining PRP, Dr. Mantripragada served as Director of R&D at Guidant Corporation, now part of Abbott Vascular. Prior to that, he served as Director of R&D and VP of Scientific Development at SkyePharma. Prior to that, he was an Assistant Professor of Biochemistry at the University of Virginia School of Medicine. Dr. Mantripragada obtained his Ph.D. in Molecular Biophysics from the Indian Institute of Science and completed a postdoctoral research program at the Max Planck Institute for Biophysical Chemistry in Germany.
 

 


chart
 
SureTrader
Interactive Brokers Advertisement
ANTB
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
ANTB News: Proxy Statement (definitive) (def 14a) 11:14 AM
ANTB News: Current Report Filing (8-k) 10/17/2017 02:06:05 PM
ANTB News: Proxy Soliciting Materials (revised) (prer14a) 10/13/2017 11:31:06 AM
ANTB News: Current Report Filing (8-k) 10/10/2017 10:52:26 AM
ANTB News: Current Report Filing (8-k) 10/05/2017 06:01:57 AM
News News Alert: Proxy Statement (definitive) (def 14a) 10/20/2017 11:14:48 AM
PostSubject
#45   Nice drop on little volume. willlbone 12/08/16 11:31:33 AM
#44   $ANTB recent news/filings stocktrademan 07/19/15 10:24:49 AM
#43   $ANTB...http://www.biospace.com/company_profile.aspx?CompanyId=1012661 hogfan2 01/09/15 10:36:17 PM
#42   $ANTB...Annouunces Appointment Of Dr. Hoyoung Huh As Chairman hogfan2 01/09/15 10:35:51 PM
#41   Colorado Roundup: AntriaBio Raises $7M, hogfan2 01/09/15 10:32:43 PM
#40   Jason Napodano, CFA ?@JNapodano 4h4 hours ago hogfan2 01/05/15 02:26:06 PM
#39   $ANTB...ANTRIABIO ANNOUNCES $7 MILLION PRIVATE PLACEMENT hogfan2 01/05/15 02:23:33 PM
#38   44M debt settlement....added to watch list. tpham83 11/14/14 02:41:54 AM
#37   WTF, a new article comes out today and dubbya 07/17/14 04:12:32 PM
#36   Is once weekly injection the future to diabetic MrDanMan 07/16/14 11:04:43 AM
#35   I've just received my 2nd invite from this Capt_Smith77 07/07/14 04:37:23 PM
#34   Andy and Opie say sell ANTB. willlbone 06/20/14 03:45:40 PM
#33   ANTB one for 6 reverse split: Renee 04/30/14 05:18:05 PM
#32   ANTB NEWS! ReLoad25 01/16/14 04:30:31 PM
#31   slow ReLoad25 12/19/13 06:13:29 PM
#30   ANTB 10Q filed pmunch 11/12/13 10:29:23 AM
#29   ANTB News!! ReLoad25 07/24/13 04:03:58 PM
#28   Appears it never left the gate pmunch 05/22/13 02:37:25 PM
#27   Looks like it wasn't an opportunity at all? dmbao 05/22/13 02:29:36 PM
#26   Seemingly endless supply of shares for sale here. dmbao 05/02/13 02:39:35 PM
#25   looks like a big pump and dump. dmbao 04/30/13 06:44:08 PM
#24   broke a dollar, something is up! fivehydroxytrypropha 04/30/13 05:14:18 PM
#23   This pullback keeps growing? dmbao 04/10/13 01:04:42 PM
#22   AntriaBio Pullback Could Spell Opportunity alexindef 03/26/13 12:08:43 PM
#21   Interesting Info ... Hope they all read it pmunch 03/18/13 10:21:26 AM
#20   http://biotechintel.com/blog/2013/3/12/antria-bio-antb Novo Nordisk - the wor alexindef 03/17/13 02:17:34 PM
#19   ..AntriaBio Set for a Major Short Squeeze zeptepi 03/14/13 12:09:27 PM
#18   New promo for ANTB https://www.otcdynamics.com/index.php/antb-antriabio-inc kyle_anderson 03/13/13 10:05:31 PM
#17   boom has been postponed... not for awhile... alexindef 02/28/13 09:24:38 PM
#16   congrats who was able to join/add today... expect alexindef 02/26/13 11:26:37 PM
#15   pps reflects the effect of BioMedReports. lol alexindef 02/22/13 11:03:04 PM
#14   Once-a-Week Insulin Shot Could Help Growing Diabetes Patient alexindef 02/22/13 09:23:25 AM
#13   http://www.linkedin.com/jobs/jobs-Scientist-Analytical-Development-4821796 Sc alexindef 02/21/13 10:22:22 AM
#12   chart has been updated in the IBox alexindef 02/20/13 11:29:06 PM
#11   AntriaBio Appoints Two Industry Leaders to Its Management Team alexindef 02/19/13 10:42:32 AM
#10   tomorrow could be last chance to enter at alexindef 02/18/13 10:46:15 PM
#9   Thank you, Renee alexindef 02/08/13 11:29:50 AM
#8   FMYY changed to ANTB: Renee 02/07/13 05:32:58 PM
#7   AntriaBio Completes Merger and Elects Board of Directors alexindef 02/07/13 09:53:15 AM
#6   http://antriabio.com/portfolio/team/ Pay attention to this guy: alexindef 01/23/13 12:42:13 PM
#5   http://antriabio.com/careers/ Clinical Development Expert alexindef 01/23/13 12:38:49 PM
#4   $2.25 x $2.45 alexindef 01/23/13 12:37:24 PM
#3   1.95 x 2.5 alexindef 01/22/13 12:29:05 PM
#2   Symbol request sent to stockcharts.com alexindef 01/20/13 07:56:40 PM
#1   IBox with a basic info has been created. alexindef 01/20/13 07:54:13 PM
PostSubject